

Resource Summary Report

Generated by [RRID](#) on Aug 31, 2026

KP-3

RRID:CVCL_3005

Type: Cell Line

Proper Citation

RRID:CVCL_3005

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3005

Proper Citation: RRID:CVCL_3005

Description: Cell line KP-3 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Pancreatic adenosquamous carcinoma

Defining Citation: [PMID:2172194](#), [PMID:18380791](#), [PMID:20215515](#), [PMID:21607521](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26216984](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:32782605](#), [PMID:35839778](#)

Comments: Population: Japanese., Part of: NCI RAS program mutant KRAS cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: KP-3

Synonyms: KP3

Cross References: BTO:BTO_0003551, CLO:CLO_0037108, EFO:EFO_0006622, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:614, BioSample:SAMN03471644, BioSample:SAMN03472945, BioSample:SAMN10987829, cancercellines:CVCL_3005, Cell_Model_Passport:SIDM00571, CGH-DB:176-1, CGH-DB:9371-4, Cosmic:918053, Cosmic-CLP:1298219, DepMap:ACH-000108, EGA:EGAS00001000610,

EGA:EGAS00001000978, GDSC:1298219, GEO:GSM827292, GEO:GSM887236, GEO:GSM888310, GEO:GSM1670003, IARC_TP53:28373, JCRB:JCRB0178.0, JCRB:NIHS0275.0, LiGeA:CCLE_616, LINCS_LDP:LCL-1723, Pharmacodb:KP3_784_2019, PRIDE:PXD030304, Progenetix:CVCL_3005, Wikidata:Q54900364

ID: CVCL_3005

Record Creation Time: 20220427T220707+0000

Record Last Update: 20260829T234426+0000

Ratings and Alerts

No rating or validation information has been found for KP-3.

No alerts have been found for KP-3.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Yuan L, et al. (2025) Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degradar of the Nuclear Pore Complex. Cancer discovery, 15(12), 2505.

Hagel KR, et al. (2023) Systematic Interrogation of Tumor Cell Resistance to Chimeric Antigen Receptor T-cell Therapy in Pancreatic Cancer. Cancer research, 83(4), 613.